MK 5478Alternative Names: MK5478
Latest Information Update: 16 Jul 2016
At a glance
- Originator Merck & Co
- Class Antihypertensives
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hypertension in Belgium (PO, Capsule)
- 12 Jan 2011 Merck completes a phase I trial in Hypertension in Belgium
- 16 Dec 2009 Phase-I clinical trials in Hypertension in Belgium (PO)